| First Author | Piera-Velazquez S | Year | 2011 |
| Journal | Am J Pathol | Volume | 179 |
| Issue | 3 | Pages | 1074-80 |
| PubMed ID | 21763673 | Mgi Jnum | J:179951 |
| Mgi Id | MGI:5304649 | Doi | 10.1016/j.ajpath.2011.06.001 |
| Citation | Piera-Velazquez S, et al. (2011) Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 179(3):1074-80 |
| abstractText | The accumulation of a large number of myofibroblasts is responsible for exaggerated and uncontrolled production of extracellular matrix during the development and progression of pathological fibrosis. Myofibroblasts in fibrotic tissues are derived from at least three sources: expansion and activation of resident tissue fibroblasts, transition of epithelial cells into mesenchymal cells (epithelial-mesenchymal transition, EMT), and tissue migration of bone marrow-derived circulating fibrocytes. Recently, endothelial to mesenchymal transition (EndoMT), a newly recognized type of cellular transdifferentiation, has emerged as another possible source of tissue myofibroblasts. EndoMT is a complex biological process in which endothelial cells lose their specific markers and acquire a mesenchymal or myofibroblastic phenotype and express mesenchymal cell products such as alpha smooth muscle actin (alpha-SMA) and type I collagen. Similar to EMT, EndoMT can be induced by transforming growth factor (TGF-beta). Recent studies using cell-lineage analysis have demonstrated that EndoMT may be an important mechanism in the pathogenesis of pulmonary, cardiac, and kidney fibrosis, and may represent a novel therapeutic target for fibrotic disorders. |
